Genmab A/S (NASDAQ:GMAB) Q4 2025 Earnings Call Transcript
Operator: Hello, and welcome to the Genmab Full Year 2025 Financial Results Conference Call. As a reminder, this conference call is being recorded.
Genmab A/S (GMAB)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Orbis Investment Management William B. Gray | 14,418,462 | $444,088,629 | +31% | 1.86% |
| 2. | Paradigm Biocapital Advisors Senai Asefaw | 7,039,834 | $216,826,887 | +85% | 5.53% |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 4,978,058 | $153,324,186 | +37% | 0.09% |
| 4. | Renaissance Technologies Jim Simons | 3,492,850 | $107,579,780 | +24% | 0.17% |
| 5. | Alyeska Investment Group Anand Parekh | 506,661 | $15,605,159 | 0.04% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,877,094 | $335,014,495 | 0.11% | |
| 2. | 4,593,901 | $141,492,141 | 0% | |
| 3. | 3,370,143 | $103,853,463 | 0.91% | |
| 4. | 1,834,439 | $56,500,775 | 0% | |
| 5. | 1,335,273 | $41,126,408 | 0.03% |
News See All
10 High Growth International Stocks to Buy Now
On February 10, Peter Boockvar, Chief Investment Officer at BFG Wealth Partners, appeared on a CNBC television interview.
Where is Genmab A/S (GMAB) Headed According to Wall Street?
Genmab A/S (NASDAQ:GMAB) is one of the best healthcare stocks under $50 to invest in.
12 Best Healthcare Stocks Under $50 to Invest In
On January 27, Jared Holz, healthcare equity strategist at Mizuho, appeared on CNBC’s 'Power Lunch' to talk about healthcare stocks and the new proposals around Medicare Advantage.
EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB)
Genmab A/S (NASDAQ:GMAB) ranks among the best high growth European stocks to buy. On January 20, H.C.
10 High Growth European Stocks To Buy
European equities began the last week of January in a sour mood, with investors concerned on January 26 about rising geopolitical tensions in anticipation of a Federal Reserve policy meeting and a flood...
Genmab (GMAB)’s Future Potential Underappreciated by Market
Orbis Investment Management released its Q4 2025 investor letter for “Orbis SICAV International Equity Fund”.
Genmab A/S (GMAB) Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside
TheFly reported on January 8 that Deutsche Bank raised its price target for GMAB to DKK 2,400 from DKK 2,000 and reiterated a Buy rating, reflecting analysts’ optimism about the company’s late-stage...
Top 10 Oncology Stocks to Buy Now
The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by 2034 with a compound annual growth rate of 11.75%.
Genmab A/S (GMAB): A Bull Case Theory
We came across a bullish thesis on Genmab A/S on Gabriel Koh’s Substack. In this article, we will summarize the bulls’ thesis on GMAB. Genmab A/S's share was trading at $33.87 as of January 13th.
Hedge Fund Resource Center Billionaire Hedge Funds
